Hypoparathyroidism, a little-known and often misdiagnosed condition, affects up to 110,000 people in Europe, with major impacts on their daily lives.
Late Diagnosis
Primarily affecting women with multiple symptoms, the diagnosis is often made late, with consequences already established: a diminished quality of life and social isolation for patients.
Numerous Consequences
Hypoparathyroidism is characterized by insufficient or absent secretion of parathyroid hormone (PTH) by the parathyroid glands, leading to hypocalcemia and, in some cases, hyperphosphatemia, with potential renal, skeletal, and cognitive consequences.
Debilitating Symptoms
The symptoms—fatigue, muscle pain, paresthesia, cognitive impairment, tetany, etc.—are nonspecific but debilitating for the patient, contributing to significant diagnostic delays and a harmful diagnostic odyssey.
Impaired Quality of Life
Despite existing treatments, many patients are unable to achieve a lasting balance in their blood calcium levels, which severely impairs their quality of life. For these individuals, there is a strong medical need for innovations capable of sustainably restoring this balance, by closely mimicking the body's natural functioning.
A Strong Medical Need for Innovations
The Hypoparathyroidism France Association emphasizes the importance of gaining a better understanding of the disease and developing therapeutic innovations to address the numerous challenges it presents.
More information on www.hypopara.fr
 Didier Galibert
|
16/06/2025 | 
Anglais
Français
Español
Italien
Português